NEWS: Curebase closes $40M Series B with strategic investment by Gilead. Read about it in TechCrunch, Fierce Biotech, andEndpoints News.

Register now
WEBINAR
The Foundations (and Future) of Digital Therapeutics and DCT
Monday, April 4th

What exactly are digital therapeutics (DTx)? How do they differ from traditional therapeutics? What is their role within the DCT landscape?

Join Mitsubishi Tanabe Pharma Holdings America’s Head of R&D and Digital Healthcare Innovation, Dr. Amir Lahav, Cognito Therapeutics' Chief Commercial Officer, Everett Crosland, Applied VR's VP of Research and Development, Todd Maddox, and Curebase’s VP of Clinical Trial Innovation, Jane Myles for an insightful discussion tackling these critical questions.

In this webinar we’ll discuss,

  • The definition of DTx and examples of currently approved or in development digital therapeutics 
  • The similarities and differences of DTx development compared to traditional Tx
  • Where the synergy between DTx and DCT lies
  • Use cases from companies with active DTx trials ... and more!
You can learn more in a 1-1 meeting with Curebase.
Request a Meeting
Or, subscribe to our blog and other educational updates.
Reserve your spot today!

The Foundations (and Future) of Digital Therapeutics and DCT

Monday, April 4th
Featured speaker:
Jane Myles
VP of Clinical Trial Innovation, Curebase
Jane Myles
VP of Clinical Trial Innovation, Curebase
Apr 4, 2022 12:00 PM
EST
free
About the Webinar
Collaborate with patient representatives for software configuration and user testing
Assist patients along their treatment journey with patient-centric software and communication tools
Closely monitor data in real-time to gain actionable insights into the patient experience

What exactly are digital therapeutics (DTx)? How do they differ from traditional therapeutics? What is their role within the DCT landscape?

Join Mitsubishi Tanabe Pharma Holdings America’s Head of R&D and Digital Healthcare Innovation, Dr. Amir Lahav, Cognito Therapeutics' Chief Commercial Officer, Everett Crosland, Applied VR's VP of Research and Development, Todd Maddox, and Curebase’s VP of Clinical Trial Innovation, Jane Myles for an insightful discussion tackling these critical questions.

In this webinar we’ll discuss,

  • The definition of DTx and examples of currently approved or in development digital therapeutics 
  • The similarities and differences of DTx development compared to traditional Tx
  • Where the synergy between DTx and DCT lies
  • Use cases from companies with active DTx trials ... and more!
You can learn more in a 1-1 meeting with Curebase

We'd love to hear from you, whether a Sponsor interested in running a study with us, a provider looking to get involved in clinical research, or patients interested in our studies. Fill out your information below and one of our team members will be in touch.

Register for webinar

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
335 S Van Ness Ave, San Francisco, CA,
94103-3627, United States